Sagimet Biosciences Ownership | Who Owns Sagimet Biosciences?


OverviewForecastFinancialsChart

Sagimet Biosciences Ownership Summary


Sagimet Biosciences is owned by 7.91% institutional investors, 8.41% insiders, and 83.69% retail investors. Baker bros. advisors lp is the largest institutional shareholder, holding 2.96% of SGMT shares.

SGMT Ownership Benchmark


TypeName% Inst% Insiders% Retail
StockSagimet Biosciences7.91%8.41%83.69%
SectorHealthcare Stocks 279.15%10.63%-189.78%
IndustryBiotech Stocks 63.94%10.67%25.38%

Institutional Shareholders


Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Baker bros. advisors lp953.00K2.96%$3.11M
Hhlr advisors724.80K2.25%$2.36M
Pfm health sciences, lp649.01K2.02%$2.12M
Millennium management160.91K0.50%$524.57K
Ikarian capital11.98K0.04%$39.07K
Simplex trading---
Shay capital---
Man group---
Schonfeld strategic advisors---
Squarepoint ops---

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Pfm health sciences, lp649.01K0.15%$2.12M
Hhlr advisors724.80K0.07%$2.36M
Baker bros. advisors lp953.00K0.03%$3.11M
Ikarian capital11.98K0.00%$39.07K
Millennium management160.91K0.00%$524.57K
Simplex trading---
Shay capital---
Man group---
Schonfeld strategic advisors---
Squarepoint ops---

Top Buyers

HolderShares% AssetsChange
Baker bros. advisors lp953.00K0.03%-
Pfm health sciences, lp649.01K0.15%-
Hhlr advisors724.80K0.07%-
Ikarian capital11.98K0.00%-
Srs capital advisors---115.00

Top Sellers

HolderShares% AssetsChange
Nea management company---2.00M
Millennium management160.91K0.00%-532.34K
683 capital management---138.26K
Citigroup---111.21K
Squarepoint ops---50.48K

Sold Out

HolderChange
Srs capital advisors-115.00
Ifp advisors-1.00K
Simplex trading-17.15K
Man group-17.32K
Shay capital-19.33K

Institutional Ownership Trends


DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Mar 31, 20256-91.43%2,545,717-85.38%70.26%1-96.77%1-94.74%
Dec 31, 2024715.97%17,500,774-10.97%551.49%3239.13%19-17.39%
Sep 30, 202467-20.24%19,656,790-6.06%611.42%23-46.51%234.55%
Jun 30, 2024843.70%20,925,652-7.45%651.08%43-34.85%22100.00%
Mar 31, 20248158.82%22,609,18756.52%770.41%66144.44%1110.00%

Recent Insider Transactions


DateNameRoleActivityValue
Jul 21, 2025Happel David President & CEOSell$598.12K
Jul 21, 2025Martins Eduardo Bruno Chief Medical OfficerSell$75.61K
Jul 21, 2025Rozek Elizabeth General Counsel and CCOSell$98.47K
Jul 23, 2024Kemble George Executive ChairmanSell$74.83K
Jul 19, 2024Martins Eduardo Bruno Chief Medical OfficerSell$25.91K

Insider Transactions Trends


DateBuySell
2025 Q3-3
2025 Q2--
2025 Q1--
2024 Q3-4
2024 Q2--

SGMT Ownership FAQ


Who Owns Sagimet Biosciences?

Sagimet Biosciences shareholders are primarily institutional investors at 7.91%, followed by 8.41% insiders and 83.68% retail investors. The average institutional ownership in Sagimet Biosciences's industry, Biotech Stocks , is 63.94%, which Sagimet Biosciences falls below.

Who owns the most shares of Sagimet Biosciences?

Sagimet Biosciences’s largest shareholders are Baker bros. advisors lp (953K shares, 2.96%), Hhlr advisors (724.8K shares, 2.25%), and Pfm health sciences, lp (649.01K shares, 2.02%). Together, they hold 7.23% of Sagimet Biosciences’s total shares outstanding.

Does Blackrock own Sagimet Biosciences?

BlackRock is not among the top 10 institutional shareholders of Sagimet Biosciences.

Who is Sagimet Biosciences’s biggest shareholder by percentage of total assets invested?

Pfm health sciences, lp is Sagimet Biosciences’s biggest shareholder by percentage of total assets invested, with 0.15% of its assets in 649.01K Sagimet Biosciences shares, valued at 2.12M$.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools